HomeFounders News › Tech News
Tech News Global Aug 27, 2026

AusperBio raises $120M Series C for hepatitis B therapy

AusperBio raises $120M Series C for hepatitis B therapy

AusperBio Therapeutics raised a $120 million Series C on Aug 27, 2026 to advance its lead hepatitis B candidate AHB-137 through a Phase 3 registrational program, backed by RA Capital, Qiming Venture Partners, CDH Investments and others. The round brings the company's total funding to $360 million since 2024.

Why this matters for founders

Biotech capital is still flowing to late-stage clinical assets; healthtech founders can cite large milestone-driven Series C rounds like this when framing staged, data-gated raises for investors.

Source: Tech Startups

Related updates

More that helps you.

Get briefs like this tuned to you.

In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.

See plans →
FoundersCheckList.AI app
Founders using FoundersCheckList.AI